SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001561743-21-000046
Filing Date
2021-06-16
Accepted
2021-06-16 07:34:42
Documents
17

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14ainvestorpresentation.htm DEFA14A 24793
2 capture10a.jpg GRAPHIC 77918
3 capture11a.jpg GRAPHIC 81316
4 capture12a.jpg GRAPHIC 82862
5 capture13a.jpg GRAPHIC 103518
6 capture14a.jpg GRAPHIC 78972
7 capture15a.jpg GRAPHIC 82381
8 capture16a.jpg GRAPHIC 88739
9 capture1a.jpg GRAPHIC 106210
10 capture2a.jpg GRAPHIC 175529
11 capture4a.jpg GRAPHIC 57326
12 capture5a.jpg GRAPHIC 99331
13 capture6a.jpg GRAPHIC 65368
14 capture7a.jpg GRAPHIC 75842
15 capture8a.jpg GRAPHIC 78353
16 capture9a.jpg GRAPHIC 68724
17 capturea.jpg GRAPHIC 82102
  Complete submission text file 0001561743-21-000046.txt   1885740
Mailing Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Business Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 650-701-7901
Kindred Biosciences, Inc. (Filer) CIK: 0001561743 (see all company filings)

IRS No.: 461160142 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36225 | Film No.: 211020495
SIC: 2834 Pharmaceutical Preparations